Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01038609 · ClinicalTrials.gov registry record · Phase 2

Hydrocodone/Acetaminophen for Acute Pain Following Bunionectomy

A Phase 2 study, sponsored by AbbVie (prior sponsor, Abbott).

Completed
Registry status
Phase 2
Development phase
250
Enrollment target

NCT01038609 is a Phase 2 study that has completed, run by AbbVie (prior sponsor, Abbott). The registered enrollment target is 250 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01038609, a Phase 2 study, has completed, sponsored by AbbVie (prior sponsor, Abbott).

COMPLETED
Registry status
Phase 2
Development phase
250 participants
Enrollment target

Study Summary

The primary purpose of this study was to evaluate analgesic efficacy and safety of hydrocodone/acetaminophen extended release compared to placebo in moderate to severe pain following primary unilateral first metatarsal bunionectomy.

Interventions

  • DRUG Placebo
  • DRUG Acetaminophen
  • DRUG Hydrocodone/Acetaminophen Extended Release
  • DRUG Morphine Extended Release

Trial Details

FieldValue
Enrollment Target 250 participants
Start Date 2009-12
Est. Completion 2010-05
Phase Phase 2

Sponsor

AbbVie (prior sponsor, Abbott)

88 total trials

What the Registry Record Tells You About NCT01038609

The ClinicalTrials.gov registry entry for NCT01038609 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 250 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AbbVie (prior sponsor, Abbott), which has 88 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.

NCT01038609 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT01038609 about?

NCT01038609 is a clinical study titled "Hydrocodone/Acetaminophen for Acute Pain Following Bunionectomy". The primary purpose of this study was to evaluate analgesic efficacy and safety of hydrocodone/acetaminophen extended release compared to placebo in moderate to severe pain following primary unilateral first metatarsal bunionectomy.

What is the current status of trial NCT01038609?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 250 participants. The study started on 2009-12. Estimated completion is 2010-05.

What interventions are being tested in trial NCT01038609?

The interventions under investigation include: Placebo (DRUG), Acetaminophen (DRUG), Hydrocodone/Acetaminophen Extended Release (DRUG), Morphine Extended Release (DRUG).

Who is sponsoring clinical trial NCT01038609?

This trial is sponsored by AbbVie (prior sponsor, Abbott), which has 88 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.